Feed ARMP
AR

Armata Pharmaceuticals, Inc. ARMP · AMEX

$3.09 +11.15% (+$0.31)

Market cap
$102.4M
Enterprise value
$392.4M
P/E
-
Forward P/E
-
PEG
-
P/S
31.0x
P/FCF
-
EV/EBITDA
-
ROIC
-47.4%
Gross margin
68.2%
Net margin
-5,825.3%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.41
Free float
31.1%

About the company

Armata Pharmaceuticals, Inc. (ARMP) is a biotechnology company focused on developing novel therapeutic options targeting infectious diseases and resistant microorganisms. The company specializes in the use of phage therapy, a method that utilizes bacteriophages, natural predators of bacteria, to combat infections. This innovative technology could offer an alternative to traditional antibiotics, especially in cases of antibiotic resistance. Armata Pharmaceuticals aims to address the challenge of microbial resistance and the need for new treatment approaches. Investors interested in advancements in the treatment of infectious diseases and novel approaches to antibiotic resistance may see potential in Armata Pharmaceuticals, Inc. (ARMP) shares for innovation in the medical industry and improved patient care.

Sector

Healthcare

Industry

Biotechnology

CEO

Deborah L. Birx

Employees

61

Headquarters

Los Angeles

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.